Lynnet Koh is the founder of Targazyme. Targazyme has raised $55M in total funding. Funding history, background and contact routes on StartupFundraising.com.
Lynnet Koh is the CEO and Founder of TargaZyme, a biopharma company focused on revolutionizing cancer medicine. She led TargaZyme's entry into the adoptive cancer immunotherapy market with the vision that it could offer a curative and preventative approach to cancer, in contrast to traditional methods that often only treat symptoms. Her company has developed a fucosylation cell efficacy multiplier "software" platform to improve the delivery and penetration of therapeutic cells.
Full founder directory · Investor directory · Company funding database · Fundraising library